Dapagliflozin for Cardio-renal Protection After ICU Discharge

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

Also called NCT07025629

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07025629
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07025629. Randomized; double masking; primary purpose treatment. Start 2025-12-02 (actual); primary completion 2029-01-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dapagliflozin for Cardio-renal Protection After ICU Discharge
Acronym
DAPA-ICU
Condition
Heart Failure and Chronic Kidney Disease Post-ICU
Intervention (Drug)
Dapagliflozin 10 MG Oral Tablet [Farxiga]
Intervention (Drug)
One tablet of placebo of dapagliflozin 10 mg
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)

Record details

Record id
cardio:ct-nct07025629
Content hash
09dcb08d4b31a161fdc3b12ef1cdd08aee0d7ac951059cc416e5fe04387f4319